Executive Briefing
Executive Briefing — Ozempic AI Monitoring
Week ending 9 August 2026
1. Headline
39 cross-response inconsistency flags were recorded this week, up 5 from last week and the highest level in the four comparable weeks. Safety and regulatory content remains the principal exposure: answers frequently address pancreatitis, contraindications, and hypoglycemia, but do not consistently include the same warnings across answer variants. Competitor visibility also rebounded sharply, led by Wegovy, Mounjaro, and Trulicity.
2. This week at a glance
| Metric | This week | Change vs. last week |
|---|---|---|
| Distinct questions / responses | 20 / 140 | Questions flat; responses +70 |
| Inconsistency flags | 39 | +5 |
| Top competitor: Wegovy | 46 mentions | +23 |
| Mounjaro | 26 | +15 |
| Trulicity | 25 | +14 |
| Pancreatitis | 45 | +19 |
| Contraindications | 42 | +20 |
| Hypoglycemia | 39 | +20 |
3. Trajectory
Safety-message inconsistency is degrading in absolute terms: flags rose from 16 on 12 July to 31, 37, 34, and now 39. The current week’s higher response volume contributes to the increase, but 39 remains the highest observed count. The 2 August dip in responses and theme counts was a volume inflection, not a durable improvement; all major themes rebounded this week.
Competitor visibility is also rising in absolute terms. Wegovy mentions increased from 16 to 46 across the period, while Mounjaro rose from 8 to 26 and Trulicity from 6 to 25. The latest week restored the high-volume pattern seen on 26 July.
4. Where the risk actually is
- Label-supported outcomes vs. Trulicity/Mounjaro (query 125): boxed warnings, contraindications, pancreatitis, pregnancy/lactation, and thyroid-tumor content appeared in some answers but were omitted in others. A user asking what can be claimed from the label may receive materially different regulatory framing.
- Warnings and symptoms (query 120): most answers included the thyroid boxed warning and serious-event information, but not all included contraindications, kidney risk, or allergic reactions. This creates uneven patient safety guidance.
- Dosing (query 118): missed-dose instructions varied between 48 hours, 5 days, and same-day rules. This is a direct usability and medication-error risk.
5. Recommended actions
- Medical Affairs + Regulatory: Create a canonical AI-ready answer set for label, contraindication, warning, pregnancy, pancreatitis, and missed-dose questions; resolve timing and terminology conflicts.
- Content/SEO: Publish concise, structured Q&A pages separating Ozempic from Wegovy, compounded semaglutide, and other products; target the 46 Wegovy and 26 Mounjaro mentions.
- PV/Medical Information: Prioritize review of queries 120, 118, and 125 and define mandatory safety elements for each response type.
- Marketing/Compliance: Audit comparative and weight-loss language, given 39 overclaim-language tags and frequent competitor framing.
- Analytics/Product: Track inconsistency rates as well as counts, segmented by question and answer variant, to distinguish volume effects from genuine improvement.